ArticleEndocrine-related cancer2026
Distinct molecular profiles of indeterminate and malignant thyroid nodules in patients under 21 years of age.
Article in Endocrine-related cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although uncommon, thyroid nodules (TNs) in pediatric and young adult patients carry a higher malignancy risk and often present with a high burden of metastatic disease than in adults. The molecular features underlying this distinct clinical behavior remain unclear. We analyzed Afirma Genomic Sequencing Classifier (GSC) data from 283,621 TNs, comparing patients <21 and ≥21 years old. Cytology (Bethesda), GSC benign (B) vs suspicious (S) calls, and Afirma Xpression Atlas (XA) variant/fusion profiles were evaluated in GSC-S and Bethesda V/VI samples. Genome-wide expression was used to derive pathway signatures and thyroid cancer-related scores: BRAF-RAS score (BRS), ERK signaling score, follicular-to-mesenchymal transition (FMT) score, epithelial-to-mesenchymal transition (EMT) score, and thyroid differentiation score (TDS). Among 2,397 patients <21 years (median age: 18.9; 81.4% female) and 281,224 adults ≥21 years (median age: 59.8; 77.1% female), the <21-year samples showed more Bethesda V/VI cytology (14.5% vs 5.0%; P < 0.0001) and a lower GSC-B rate (43.5% vs 68.8%; P < 0.0001). In GSC-S samples, total variant detection was higher in the <21-year group (45.3% vs 37.4%), with enriched BRAF p.V600E, TSHR, and DICER1 variants, while HRAS variants were more common in adults (all P < 0.01). Gene fusions involving RET, NTRK3, and ALK were enriched in the <21-year group (14.5% vs 5.5%; P < 0.0001). TERT promoter mutations were absent in <21-year GSC-S and Bethesda V/VI samples (vs 4.2% and 9.3% in adults). The GSC-S <21-year cohort showed cell-cycle pathway enrichment. The RET/NTRK/ALK-positive <21-year group demonstrated enrichment of angiogenesis and EMT pathways, higher ERK/EMT/FMT scores, and lower BRS/TDS vs genotyped-matched adults. These molecular differences provide mechanistic insight into the more invasive phenotype in pediatric and young adult TNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.